AstraZeneca PLC And MedImmune Release: New Study Reveals Significant Burden Of RSV Disease Among U.S. Preterm Infants Born At 32-35 Weeks

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WILMINGTON, Del.--(BUSINESS WIRE)--The MedImmune Specialty Care division of AstraZeneca (MedImmune Specialty Care) announced today the publication of results from a new study that examined the burden of Respiratory Syncytial Virus (RSV) in preterm infants not receiving RSV immunoprophylaxis. The “RSV Respiratory Events Among Preterm Infants Outcomes and Risk Tracking” (REPORT) study is the first large, prospective study with active surveillance for laboratory-confirmed RSV disease in U.S. preterm infants born between 32 and 35 weeks gestational age (wGA). The study was published in the June issue of The Pediatric Infectious Disease Journal.

Help employers find you! Check out all the jobs and post your resume.

Back to news